JPMorgan Smaller Cos IT PLC
26 March 2008
Form TR-1 with annex. FSA Version 2.1 updated April 2007
TR-1: Notifications of Major Interests in Shares
1. Identity of the issuer or the underlying issuer of existing JPMorgan Smaller Companies Investment
shares to which voting rights are attached: Trust plc
2. Reason for notification (yes/no) Yes
Other (please specify): change of issued share capital JPMorgan Chase & Co
3. Full name of person(s) subject to notification
obligation: JPMorgan Asset Management (UK) Limited
4. Full name of shareholder(s) (if different from 3): 30 November 2007
5. Date of transaction (and date on which the
threshold is crossed or reached if different): 25 March 2008
6. Date on which issuer notified: 13%
7. Threshold(s) that is/are crossed or reached:
8: Notified Details
A: Voting rights attached to shares
Class/type of Situation previous to the Resulting situation after the triggering transaction
shares triggering transaction
Number of Number of Number of Number of voting rights Percentage of voting
If possible use shares voting rights shares rights
ISIN code
Direct Indirect Direct Indirect
GB0007416000 2,740,835 2,740,835 2,710,335 2,710,335 13.04%
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial Expiration date Exercise/ conversion No. of voting rights that Percentage of voting
instrument period/date may be acquired (if the rights
instrument exercised/
converted)
N/A
Total (A+B)
Number of voting rights Percentage of voting rights
2,710,335 13.04%
9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are
effectively held, if applicable:
Total disclosable holding for JPMorgan Chase & Co. : 2,710,335 (13.04%)
JPMorgan Asset Management (UK) Limited: 2,710,335 (13.04%)
Proxy Voting:
10. Name of proxy holder: N/A
11. Number of voting rights proxy holder will cease N/A
to hold:
12. Date on which proxy holder will cease to hold N/A
voting rights:
13. Additional information: Please note the group has other holdings which are
covered by exemptions.
14 Contact name: Michael Kirwan
15. Contact telephone name: 020 7325 4513
For notes on how to complete form TR-1 please see the FSA website.
Note: Annex should only be submitted to the FSA not the issuer
Annex: Notification of major interests in shares
A: Identity of the persons or legal entity subject to the notification obligation
Full name JPMorgan Chase & Co
(including legal form of legal entities)
Contact address 270 Park Avenue, New York, NY10017
(registered office for legal entities)
Phone number & email 001 212 270 6000
Other useful information N/A
(at least legal representative for legal persons)
B: Identity of the notifier, if applicable
Full name Michael Kirwan
Contact address JPMorgan Chase, 13th Floor, 125 London Wall, London,
EC2Y 5AJ
Phone number & email 020 7325 4513
michael.d.kirwan@jpmorgan.com
Other useful information N/A
(e.g. functional relationship with the person or
legal entity subject to the notification obligation)
C: Additional information
N/A
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.